...CFO. A former investment banker, Leiderman was most recently CBO of fibrosis and inflammatory disease company Complexa...

...for rare diseases at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). Fibrotic and inflammatory disease company Complexa Inc....
...Flexion Therapeutics (NASDAQ:FLXN). Hongjiang Li and Elizabeth S. Eaton, Staff Writers Dyne Therapeutics Inc. Imara Inc. Pharvaris B.V. DBV Technologies S.A. Complexa Inc....

...RTA 402, CDDO-Me) in Phase II or Phase III testing for four renal indications, and Complexa Inc....

...John Kirby to CFO from VP of finance. Tarka was VP of clinical development at Complexa Inc....

...Fibrotic and inflammatory disease company Complexa Inc. (Berwyn, Pa.) hired Francisco Salva as president and CEO. He...

...fund, participating in a $62 million series C round for renal, cardiovascular and hematology company Complexa Inc....

...far, participating in a $62 million series C round for renal, cardiovascular and hematology play Complexa Inc....

...Rare disease play Complexa Inc. (Pittsburgh, Pa.) raised $62 million on July 26 in a series C...
...HBM Healthcare Investments also participated, as did existing investor JAFCO. Complexa Inc. , Pittsburgh, Pa. Elizabeth S. Eaton Complexa Inc....

...Rare disease play Complexa Inc. (Pittsburgh, Pa.) raised $62 million in a series C round led by...
...Partners and HBM Healthcare Investments also participated, as did existing investor JAFCO. In early 2018, Complexa...
...led Complexa’s series B financing in 2014 (see BioCentury Extra, June 4, 2014) . Elizabeth S. Eaton CXA-10 Complexa Inc....

...ATGR1) antagonist, and propagermanium, a CC chemokine receptor 2 (CCR2; CD192) antagonist FSGS Phase II Complexa Inc....